You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 87 No. 6, JUNE 1951 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

EFFECTS OF VERILOID® ON ESSENTIAL HYPERTENSION

A New Derivative of Veratrum Viride

ARTHUR L. GROPPER, M.D.; A. SURTSHIN, M.D.; JAMES T. HEDRICK, M.D.

AMA Arch Intern Med. 1951;87(6):789-794.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

INTEREST in the use of preparations of Veratrum viride for treatment of essential hypertensive vascular disease has recently been revived. This interest stems from a number of reports indicating favorable effects on blood pressure and a better understanding of the pharmacologic action of the Veratrum alkaloids.1 The preparations employed clinically have been, for the most part, mixtures of alkaloids said to be therapeutically effective and efficiently nontoxic for extended use. More recently,2 oral administration of a purified alkaloidal fraction of Veratrum viride, standardized on a chemical basis and given the proprietary name veriloid,®1b has been reported to produce lowering of blood pressure for periods as long as five months, while accompanied with "fewer toxic reactions than any other oral preparation of Veratrum viride presently available."2 Its pharmacologic actions have been described.3 Because of the promising clinical results reported, we studied the effects on arterial pressure . . . [Full Text PDF of this Article]


Author Affiliations

ST. LOUIS; GARY, IND.

From the Hypertension Division, Department of Internal Medicine, the Department of Physiology and the Division of Gerontology, Washington University School of Medicine, and the Homer G. Phillips, St. Louis City and Barnes Hospitals, under a Grant-in-Aid from Eli Lilly & Company, Indianapolis 6, and the National Heart Institute.


Footnotes

The Riker Laboratories, Inc., Los Angeles 48, supplied the veriloid® used in this study.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1951 American Medical Association. All Rights Reserved.